Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the business's stock in a transaction dated Tuesday, February 25th. The shares were purchased at an average price of $4.46 per share, with a total value of $44,600.00. Following the acquisition, the chief executive officer now directly owns 2,331,730 shares in the company, valued at approximately $10,399,515.80. The trade was a 0.43 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Mihael Hristos Polymeropoulos also recently made the following trade(s):
- On Friday, February 28th, Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock. The shares were purchased at an average price of $4.76 per share, with a total value of $47,600.00.
Vanda Pharmaceuticals Trading Up 1.3 %
Vanda Pharmaceuticals stock traded up $0.06 during trading on Friday, hitting $4.76. The company had a trading volume of 487,887 shares, compared to its average volume of 653,259. Vanda Pharmaceuticals Inc. has a 1-year low of $3.71 and a 1-year high of $6.75. The company's 50 day simple moving average is $4.59 and its 200-day simple moving average is $4.80. The stock has a market cap of $277.58 million, a price-to-earnings ratio of -14.88 and a beta of 0.74.
Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.06. The business had revenue of $53.19 million during the quarter, compared to the consensus estimate of $51.00 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. As a group, analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on VNDA shares. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a "hold" rating for the company. HC Wainwright lifted their target price on shares of Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a "buy" rating in a report on Tuesday, February 18th.
Read Our Latest Stock Report on Vanda Pharmaceuticals
Hedge Funds Weigh In On Vanda Pharmaceuticals
Several institutional investors have recently modified their holdings of VNDA. SG Americas Securities LLC grew its stake in shares of Vanda Pharmaceuticals by 88.5% in the third quarter. SG Americas Securities LLC now owns 20,402 shares of the biopharmaceutical company's stock worth $96,000 after acquiring an additional 9,580 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Vanda Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 4,374 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter worth $143,000. Empowered Funds LLC lifted its position in shares of Vanda Pharmaceuticals by 5.3% during the 3rd quarter. Empowered Funds LLC now owns 228,287 shares of the biopharmaceutical company's stock worth $1,071,000 after purchasing an additional 11,524 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Vanda Pharmaceuticals by 7.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 780,933 shares of the biopharmaceutical company's stock worth $3,663,000 after purchasing an additional 55,567 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company's stock.
About Vanda Pharmaceuticals
(
Get Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Further Reading
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
